Hypersomatostatinemia in chronic renal failure

Area of Science:

• Endocrinology
• Nephrology
• Biochemistry

Background:

• Uremia, a condition of kidney failure, is associated with various metabolic disturbances.
• Somatostatin, a peptide hormone, plays a role in regulating numerous physiological processes.
• Altered peptide hormone levels are often observed in patients with chronic kidney disease.

Purpose of the Study:

• To investigate plasma somatostatin-like immunoreactivity (SLI) levels in uremic patients undergoing maintenance hemodialysis.
• To characterize the forms of somatostatin present in the circulation of uremic individuals.
• To compare SLI levels between diabetic and non-diabetic uremic patients and healthy controls.

Main Methods:

• Plasma samples were collected from uremic patients (diabetic and non-diabetic) and healthy controls.
• Plasma SLI was quantified using radioimmunoassay.
• Chromatographic techniques, including reverse-phase cartridge purification and Sephadex G-25 gel filtration, were employed to separate and identify SLI components.

Main Results:

• Plasma SLI levels were significantly elevated in both diabetic (67.1 pg/ml) and non-diabetic (43.5 pg/ml) uremic patients compared to healthy subjects (5.0 pg/ml).
• Chromatographic analysis revealed two main peaks of SLI, co-eluting with somatostatin-28 (SS-28) and somatostatin-14 (SS-14) markers.
• The SS-28-like immunoreactivity (LI) peak was substantially larger (approximately 75% of total SLI), indicating SS-28 is the predominant circulating form.

Conclusions:

• Uremic patients exhibit markedly elevated plasma SLI, irrespective of diabetic status.
• Somatostatin-28 is the predominant circulating form of somatostatin in uremic patients.
• Reduced clearance of SS-28 may contribute to its elevated levels in uremia.